3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Climb Bio and Mabworks reported additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, presented at ASN Kidney Week 2026. The data show an estimated half-life of about 33 days and, at 12 weeks after an 800 mg dose, reductions of about 70% in Gd-IgA1 and about 60% in IgA. The filing contains no revenue or earnings figures, and the next key milestone remains initial data from the NAVIGATE-2 Phase 2 trial in the first half of 2027.
Estimated half-life of approximately 33 days, based on the 800 mg and 320 mg multiple-ascending dose cohorts
Free APRIL suppression of 90% or more through 12 weeks after a single subcutaneous dose of 480 mg or higher
About 70% Gd-IgA1 and about 60% IgA reduction at 12 weeks after a single 800 mg dose, the NAVIGATE-2 loading dose
Injection site reactions in 5 of 88 participants, all Grade 1; initial NAVIGATE-2 data expected in the first half of 2027
Medicus Pharma Ltd. said Nasdaq notified it on October 23, 2026 that it had regained compliance with the $1.00 minimum bid price requirement and that the matter is closed. The notice supersedes an October 20, 2026 delisting determination letter that would have removed the company's shares and warrants from The Nasdaq Capital Market. The company states there can be no assurance it will maintain compliance in the future.
Nasdaq notified the company on October 23, 2026 that it regained compliance with the $1.00 minimum bid price requirement.
The closing bid price was at or above $1.00 for ten consecutive business days, from October 12 to October 23, 2026.
An October 20, 2026 delisting determination letter was superseded and rendered moot by the compliance notice.
Earlier, Nasdaq had found the company ineligible for a second 180-day compliance period because it does not meet the minimum $5 million stockholders' equity requirement.
First Capital, Inc. (NASDAQ: FCAP) reported third-quarter 2026 net income of $5.1 million, or $1.53 per diluted share, up from $4.5 million, or $1.34, a year earlier. The tax-equivalent net interest margin rose to 4.08% from 3.71%, while the provision for credit losses increased to $355,000 from $150,000. For shareholders, quarterly and nine-month earnings per share both increased compared with 2025.
Q3 2026 net income was $5.1 million, or $1.53 per diluted share, versus $4.5 million, or $1.34, in Q3 2025.
Nine-month 2026 net income was $14.2 million, or $4.25 per diluted share, versus $11.5 million, or $3.43, a year earlier.
Tax-equivalent net interest margin was 4.08% for the quarter versus 3.71%; nonperforming assets rose to $5.5 million from $4.4 million at December 31, 2025.
Avidia Bancorp, Inc. reported third quarter 2026 net income of $8.6 million, or $0.47 per share, up from $7.2 million, or $0.39 per share, in the second quarter, and total net revenue rose 4% to $31.2 million. The company also declared a $0.06 per share quarterly cash dividend and said it had completed $23.8 million of share repurchases under a $30 million authorization as of September 30. The filing notes that net interest margin included a $692 thousand loan prepayment penalty.
Net income of $8.6 million ($0.47 per share) vs. $7.2 million ($0.39 per share) in the prior quarter; the company had a net loss of $907 thousand in the third quarter of 2025
Total net revenue of $31.2 million, up $1.3 million, or 4%, from the prior quarter
Quarterly dividend of $0.06 per share, payable on or about November 30, 2026, to holders of record on November 17, 2026
Share repurchases of $23.8 million completed as of September 30, 2026, against a $30 million authorization
Alaunos Therapeutics said Nasdaq confirmed it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, closing the matter and canceling the November 10, 2026 hearing before the Nasdaq Hearings Panel. Its common stock will continue to be listed and traded on The Nasdaq Capital Market, removing the near-term delisting risk for shareholders.
Nasdaq notified the company on April 9, 2026 that it was not in compliance with the $2,500,000 stockholders' equity requirement.
The company said a private placement completed on October 14, 2026 led it to believe it had regained compliance.
On October 22, 2026, Nasdaq's Office of General Counsel confirmed compliance and closed the matter.
The hearing scheduled for November 10, 2026 was cancelled.
Delek Logistics Partners declared a third quarter 2026 cash distribution of $1.14 per common limited partner unit, or $4.56 annualized, according to the 8-K and attached press release. The filing describes this as an increase in the quarterly cash distribution, and unitholders of record on November 3, 2026 will receive the payment on November 10, 2026.
Third quarter 2026 distribution: $1.14 per common limited partner unit ($4.56 annualized)
Record date November 3, 2026; payment date November 10, 2026
Delek US Holdings, Inc. owns the general partner and a majority limited partner interest
MacroGenics presented interim Phase 1 data for MGC026, an investigational B7-H3-directed antibody-drug conjugate, at the ESMO 2026 Congress on October 23, 2026. In 22 response-evaluable head and neck cancer patients, the best overall response rate was 27% (6/22), and the company plans a front-line study combining MGC026 with pembrolizumab in early 2027. The data are preliminary, and the filing discloses no revenue, earnings or financing figures.
Best overall response rate of 27% (6/22) in the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort, including four confirmed and two unconfirmed partial responses
Grade 3 or higher treatment-related adverse events occurred in 51% of the 85-patient overall safety population, and 5% discontinued treatment
Plans to start a front-line SCCHN expansion cohort with pembrolizumab in early 2027; updated Stage 2 data expected in mid-2027
MetroCity Bankshares reported third-quarter 2026 net income of $24.3 million, or $0.84 per diluted share, up from $22.1 million ($0.76) in the second quarter and $17.3 million ($0.67) in the third quarter of 2025. The company said the quarter-over-quarter increase mainly reflected a $4.8 million decrease in income tax expense, while net interest margin slipped to 4.07% from 4.11%, and the year-over-year growth reflected the First IC acquisition completed in the fourth quarter of 2025.
Q3 2026 net income of $24.3 million, up 9.8% from $22.1 million in Q2 2026 and 40.7% from $17.3 million in Q3 2025
Diluted earnings per share of $0.84, compared with $0.76 in Q2 2026 and $0.67 in Q3 2025
Net interest margin of 4.07%, down from 4.11% in Q2 2026 but up from 3.68% in Q3 2025
Nine-month 2026 net income of $68.7 million, or $2.37 per diluted share, compared with $50.4 million, or $1.96, a year earlier
Zevia agreed on October 22, 2026 to sell up to $20 million of Series A Senior Convertible Preferred Stock to Bubble Holdings, an affiliate of GP Investments; $15 million closed that day and the remaining $5 million depends on 2026 net sales and Adjusted EBITDA targets. The company also said preliminary third quarter 2026 net sales are about $48 million, above its prior $44 million to $46 million guidance, and Adjusted EBITDA is expected to be between negative $900 thousand and negative $1.0 million, better than its prior negative $3.0 million to negative $3.5 million range, though the convertible preferred is dilutive to common shareholders.
$15 million of Series A Preferred Stock issued October 22, 2026; remaining $5 million deferred closing requires 2026 net sales of at least $172.5 million and Adjusted EBITDA of no less than negative $3.0 million
Preferred accrues a 6.00% dividend and converts initially at $1.448 per share, with conversion capped at 14,428,844 shares
Purchaser gets the right to designate one board director; board size increased to eight members
Preliminary Q3 2026 net sales about $48 million vs. prior guidance of $44 million to $46 million; full results due November 4, 2026
Consumer Portfolio Services reported third quarter 2026 revenue of $131.9 million, up 21.7%, and net income of $7.0 million, up 43.3% from a year earlier. Diluted earnings per share were $0.30, up from $0.20, and the company said net income grew faster than revenue as loan origination volume increased. Shareholders should note that operating expenses also rose, mainly from interest expense tied to higher loan volume.
Diluted EPS was $0.30 for Q3 2026, up 50% from $0.20 in Q3 2025; nine-month diluted EPS was $0.80 versus $0.59.
Total revenue was $131.9 million, up from $108.4 million; total operating expenses were $121.8 million, up from $101.4 million.
Contracts purchased rose 108.5% to $815.3 million, and the loan portfolio reached $4.711 billion, up 25.3%.
Conference call and webcast are scheduled for October 26, 2026, at 1:00 p.m. ET.
Ionis partner Roche announced Phase 3 IMAgINATION data showing investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with IgA nephropathy. Roche plans to share the data with health authorities, and the filing says Ionis is eligible for regulatory and sales milestone payments and tiered royalties on net sales of sefaxersen.
Proteinuria reduction of 43.1% vs. placebo at 37 weeks (95% CI: 32.5 to 52.0; P<0.0001)
Treatment effect consistent across all prespecified subgroups; no new safety signals reported
Study enrolled 459 people and will continue as a blinded study to assess eGFR at week 105
Roche will share data with health authorities; Ionis may receive regulatory and sales milestone payments and royalties
Perspective Therapeutics reported updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET in advanced SSTR2-expressing neuroendocrine tumors, presented at the ESMO Congress 2026 on October 23, 2026. The company reported objective response rates of 33% in Cohort 2 and 50% in Cohort 3, with no dose-limiting toxicities and no discontinuations due to adverse events, and it aims to complete Phase 3 site start-up preparations around year-end 2026. The data are early and based on small cohorts, so the results may not hold as the trial continues.
Objective response rate was 33% (15 of 46) in Cohort 2 at 5.0 mCi and 50% (10 of 20) in Cohort 3 at 6.0 mCi, including unconfirmed responses
Progression-free survival was 72% at 18 months across all patients who received at least one treatment
20 of 68 patients (29%) had high-grade treatment-emergent adverse events, all Grade 3; no dose-limiting toxicities were reported
Phase 3 site start-up preparations targeted around year-end 2026, with Phase 3 initiation expected in 2027 following an End-of-Phase 2 meeting with the FDA
Tompkins Financial reported third-quarter 2026 diluted earnings per share of $2.00 and net income of $28.7 million, up 21.2% and 21.0% from a year earlier but down 2.0% and 2.2% from the second quarter of 2026. The board also declared a $0.74 per share dividend, payable November 13, 2026, to shareholders of record on November 6, 2026.
Q3 2026 diluted EPS of $2.00, up from $1.65 in Q3 2025 and down from $2.04 in Q2 2026
Nine-month 2026 diluted EPS of $5.86, up 29.6% from $4.52 a year earlier
Net interest margin of 3.65% in Q3 2026, up 45 basis points from 3.20% in Q3 2025
Noninterest income fell 46.7% year over year, mainly due to the sale of insurance subsidiary TIA in Q4 2025
The Gorman-Rupp Company reported third-quarter 2026 results for the period ended September 30, 2026, with net sales of $193.3 million, up 11.8% from a year earlier, and net income of $22.7 million, or $0.86 per share, versus $11.3 million, or $0.43 per share, in the third quarter of 2025. For shareholders, the filing shows higher earnings and lower interest expense, along with total debt reduced by $58.0 million in the first nine months of 2026.
Third-quarter net sales of $193.3 million rose $20.4 million, or 11.8%, from $172.8 million in the third quarter of 2025
Net income was $22.7 million, or $0.86 per share, compared with $11.3 million, or $0.43 per share, a year earlier
Total debt decreased $58.0 million during the first nine months of 2026
Full-year 2026 capital expenditures are presently planned at approximately $22.0 to $24.0 million
Tempus AI announced agreements with Bristol-Myers Squibb and Pathos AI to expand use of its de-identified real-world data, software and models, with aggregate cash payments to Tempus of $192.5 million over about five years. The Pathos neurology deal is a related-party transaction, reviewed and approved by a special committee of disinterested directors, which shareholders may weigh when assessing the agreements.
BMS oncology Statement of Work runs through December 31, 2031, with $137.5 million in fixed payments invoiced quarterly.
Pathos Neuro Order Form provides up to $55 million, including $100 per delivered record and $5.0 million for record updates; the total depends on records delivered.
Pathos is a related party because of overlapping executive leadership and equity ownership, so a special committee of disinterested directors approved the neurology deal.
Sierra Bancorp's board approved a new share repurchase program for up to 1,000,000 shares, running from the end of the current program on October 31, 2026 through October 31, 2027, and declared a $0.27 per share quarterly cash dividend. The new program replaces the current one, under which 381,532 shares remain available. The filing gives no earnings figures, but the buyback and steady dividend return capital to shareholders.
New repurchase program authorizes up to 1,000,000 shares, running from November 1, 2026 through October 31, 2027
381,532 shares remain under the current program expiring October 31, 2026
Quarterly cash dividend of $0.27 per share, payable November 9, 2026 to holders of record on November 2, 2026
Dividend marks the company's 111th consecutive quarterly cash dividend
First National Corporation reported net income of $6.9 million, or $0.76 per basic share, for the quarter ended September 30, 2026, compared with $5.55 million, or $0.62 per share, a year earlier. For the nine months, net income was $17.5 million, or $1.94 per basic share, versus $12.2 million, or $1.36, in the same period of 2025. The company also said it expects a one-time gain in the fourth quarter from the early October sale of two North Carolina banking offices, though the filing does not state the amount.
Q3 2026 net income of $6.9 million and basic EPS of $0.76, versus $5.55 million and $0.62 in Q3 2025
Net interest margin (FTE) of 4.38% for Q3 2026, up from 3.84% a year earlier
Nine-month 2026 net income of $17.5 million and basic EPS of $1.94, versus $1.36 a year earlier
Tangible book value per share was $19.94 on September 30, 2026, up from $18.26 on September 30, 2025
ORIC Pharmaceuticals presented updated Phase 1b data for its enozertinib (ORIC-114) program at ESMO Congress 2026 on October 23, 2026, reporting an 84% investigator-assessed systemic response rate and a 70% investigator-assessed intracranial response rate in 26 patients with EGFR atypical NSCLC. The company plans to start a global Phase 3 trial, Redwood-1, in the first half of 2027. The filing contains clinical data only and no financial results, so the update's effect on shareholders depends on future trial outcomes and funding.
Investigator-assessed systemic ORR was 84% (21 of 25); BICR-assessed systemic ORR was 80% (20 of 25) as of the September 4, 2026 cutoff
BICR RANO-BM intracranial ORR was 67% (10 of 15), with a 40% (6 of 15) complete response rate
Six patients (23%) had Grade 3 treatment-related adverse events, all resolved with dose modifications; no Grade 4 or 5 events were reported
Redwood-1 Phase 3 trial plans to enroll approximately 360 patients, with initiation planned for the first half of 2027
Republic Bancorp reported third quarter 2026 net income of $31.1 million, or $1.59 per diluted share, up from $29.7 million, or $1.52, a year earlier. For the nine months ended September 30, 2026, net income fell 2% to $106.5 million, and diluted EPS fell to $5.44 from $5.55.
Q3 2026 net income $31.1 million, up 4% from $29.7 million in Q3 2025; diluted EPS $1.59 vs. $1.52.
Nine-month 2026 net income $106.5 million, down 2% from $108.5 million; diluted EPS $5.44 vs. $5.55.
Core Banking net interest income rose $4.8 million, or 8%, to $66.1 million; net interest margin expanded 25 basis points to 4.03%.
Republic Credit Solutions net income fell 15% to $6.2 million, reflecting higher provision expense and noninterest expense.
World Acceptance Corporation reported fiscal 2027 second quarter results for the three months ended September 30, 2026, swinging to net income of $8.8 million, or $1.92 per diluted share, from a net loss of $1.7 million a year earlier. Total revenues rose 3.2% to $139.2 million, and the provision for credit losses fell to $46.0 million, while gross loans were roughly flat year over year at $1.319 billion.
Q2 net income of $8.8 million, or $1.92 per diluted share, versus a net loss of $1.7 million, or $0.33 per diluted share, a year earlier
Total revenues increased 3.2% to $139.2 million; net charge-offs rose to 17.6% of average net loans on an annualized basis from 17.1%
Company repurchased 133,199 shares for approximately $25.0 million in the quarter; about $25.0 million remained under the current repurchase program as of September 30, 2026
Six-month results included $4.8 million in expense related to the CEO transition; adjusted net income was $18.5 million, or $4.05 per diluted share
Balchem reported results for the quarter ended September 30, 2026, with net sales of $290.7 million, up 8.6% from the prior year quarter, and GAAP net earnings of $46.7 million, up 16.0%. Diluted GAAP earnings per share were $1.46 versus $1.24, and all three reporting segments grew sales and earnings from operations, which points to improving results for shareholders.
Net sales were $290.7 million, up 8.6%; GAAP net earnings were $46.7 million, up 16.0%.
GAAP diluted EPS was $1.46 versus $1.24; adjusted EPS was $1.57 versus $1.35.
Free cash flow was $57.9 million; the company repurchased about $28 million of common stock in the quarter.
Net debt was $57.7 million with a leverage ratio of 0.2 times on a net debt basis.
American Express reported third-quarter 2026 net income of $3.7 billion, up from $2.9 billion a year earlier, and diluted EPS of $5.42, up 31%. Excluding a $982 million pre-tax gain from the sale of its GBTG stake and a $336 million pre-tax restructuring charge, adjusted EPS was $4.68, up 13%. The company raised its full-year 2026 EPS guidance to $18.30 to $18.60 ($17.60 to $17.90 adjusted), which signals higher expected earnings for shareholders.
Total revenues net of interest expense were $20.1 billion, up 9% year over year, with billed business up 8% to $454.0 billion in the quarter.
Diluted EPS was $5.42 versus $4.14 a year ago; adjusted EPS was $4.68 versus $4.14.
Full-year 2026 EPS guidance was raised to $18.30 to $18.60, or $17.60 to $17.90 adjusted.
Provisions for credit losses fell to $1.0 billion from $1.3 billion, and the net write-off rate was 1.8% versus 1.9% a year ago.
Zymeworks signed a Collaboration and License Agreement with Roche on October 22, 2026, giving Roche exclusive worldwide rights to develop and commercialize its ZW209 DLL3-targeting trispecific T-cell engager. The deal includes a $55 million upfront payment and up to $718 million in milestones, and it takes effect only after U.S. Hart-Scott-Rodino clearance, while Roche can terminate at any time.
Upfront non-refundable payment of $55 million, due after HSR Clearance
Non-refundable $40 million milestone on initiation of the Phase Ib Trial, plus up to $718 million in other milestones
Tiered high-single-digit to mid-teen royalties on annual net sales, with Zymeworks conducting the Phase Ia trial at Roche's expense
Roche may terminate the agreement in its sole discretion at any time; Zymeworks' exclusivity restriction runs up to five years
Primis Financial reported third-quarter 2026 net income available to common shareholders of $8.7 million, or $0.35 per diluted share, up from $6.8 million, or $0.28, a year earlier. Nine-month net income fell to $25.4 million from $31.9 million, partly because the 2025 period included $32.0 million of investment gains, and the company also declared a $0.10 quarterly dividend.
Q3 2026 net income of $8.7 million, or $0.35 per diluted share, versus $6.8 million, or $0.28, in Q3 2025
Nine-month 2026 net income of $25.4 million, or $1.03 per diluted share, versus $31.9 million, or $1.29, in the same period of 2025
Net interest margin of 3.66% in Q3 2026 versus 3.18% a year earlier; CEO said retail mortgage pipeline fell 37%
Quarterly dividend of $0.10 per share payable November 20, 2026, to shareholders of record on November 6, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.